In vitro and in vivo evaluation of a sublingual fentanyl wafer formulation

Drug Design, Development and Therapy

Volumn 7, Issue , 2013, Pages 317-324

  Lim, Stephen C B ^a,d   Paech, Michael J ^b,c   Sunderland, Bruce ^d   Liu, Yandi ^d  

^a Armadale Health Service   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c KING EDWARD MEMORIAL HOSPITAL   (Australia)

^d CURTIN UNIVERSITY   (Australia)

Author keywords

Absolute bioavailability; Fentanyl wafer; In vitro dissolution; In vivo study; Pharmacokinetics; Sublingual

Indexed keywords

CARBOXYMETHYLCELLULOSE; FENTANYL; FENTANYL CITRATE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISPERSION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG RELEASE; DRUG SCREENING; DRUG SOLUBILITY; DRUG SYNTHESIS; FEMALE; FREEZE DRYING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIMIT OF DETECTION; MAXIMUM PLASMA CONCENTRATION; MOISTURE; PHYSICAL CHEMISTRY; PILOT STUDY; PLASMA CONCENTRATION-TIME CURVE; RANDOMIZED CONTROLLED TRIAL; SCANNING ELECTRON MICROSCOPY; TABLET DISINTEGRATION TIME; TABLET FRIABILITY; TABLET PROPERTY; TABLET WEIGHT; TIME TO MAXIMUM PLASMA CONCENTRATION; X RAY DIFFRACTION;

ABSOLUTE BIOAVAILABILITY; FENTANYL WAFER; IN VITRO DISSOLUTION; IN VIVO STUDY; PHARMACOKINETICS; SUBLINGUAL;

ADMINISTRATION, SUBLINGUAL; ADULT; AGED; ANALGESICS, OPIOID; BIOLOGICAL AVAILABILITY; CARBOXYMETHYLCELLULOSE SODIUM; CROSS-OVER STUDIES; EXCIPIENTS; FEMALE; FENTANYL; FREEZE DRYING; HUMANS; MICROSCOPY, ELECTRON, SCANNING; MIDDLE AGED; PILOT PROJECTS; SOLUBILITY; X-RAY DIFFRACTION; YOUNG ADULT;

EID: 84876253360     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S42619     Document Type: Article

References (22)

1. AHFS Drug Information. Fentanyl Citrate Monograph. Bethesda, MD: American Society of Health-System Pharmacist; 1996;98:1466-1470.
2. Mock DL, Streisand JB, Hague B, et al. Transmucosal narcotic delivery: an evaluation of fentanyl (lollipop) premedication in man. Anesth Analg. 1986;65:S102.
3. Lee M, Kern SE, Kisicki JC, Egan D. A pharmacokinetic study to compare two simultaneous 400 μg doses with a single 800 μg dose of oral transmucosal fentanyl citrate. J Pain Symptom Manage. 2003;26:743-747.
4. Zhang H, Zhang J, Streisand J. Oral mucosal drug delivery clinical pharmacokinetics and therapeutic applications. Clin Pharmacokinet. 2002;41:661-680.
5. Lichtor JL, Sevarino FB, Joshi GP, Busch MA, Nordbrock E, Ginsberg B. The relative potency of oral transmucosal fentanyl citrate compared with intravenous morphine in the treatment of moderate to severe postoperative pain. Anesth Analg. 1999;89:732-738.
6. Vasisht N, Gever LN, Tagarro I, Finn AL. Single-dose pharmacokinetics of fentanyl buccal soluble film. Pain Med. 2010;11:1017-1023.
7. Reisfield GM, Wilson GR. Rational use of sublingual opioids in palliative medicine. J Palliat Med. 2007;10:465-475.
8. Überall MA, Müller-Schwefe GH. Sublingual fentanyl orally disintegrating tablet in daily practice: efficacy, safety and tolerability in patients with breakthrough cancer pain. Curr Med Res Opin. 2011;27: 1385-1394.
9. Bredenberg S, Duberg M, Lennernäs B, et al. In vitro and pharmacokinetic evaluation of a new sublingual tablet system for rapid oromucosal absorption using fentanyl citrate as the active substance. Eur J Pharm Sci. 2003;20:327-334.
10. Lennernas B, Hedner T, Holmberg M, Bredenberg S, Nystrom C, Lennernas H. Pharmacokinetics and tolerability of different doses of fentanyl following sublingual administration of a rapidly dissolving tablet to cancer patients: a new approach to treatment of incident pain. Br J Clin Pharmacol. 2004;59:249-253.
11. Lim CBS, Schug SA, Sunderland VB, Paech JM, Liu Y. A phase I pharmacokinetic and bioavailability study of a sublingual fentanyl wafer in healthy volunteers. Anesth Analg. 2012;115:554-559.
12. Gardner-Nix J. Oral transmucosal fentanyl and sufentanil for incident pain. J Pain Symptom Manage. 2001;22:627-630.
13. British Pharmacopoeia Commission. British Pharmacopoeia 2009. London, UK: The Stationery Office; 2008.
14. Garsuch V, Breitkreutz J. Novel analytical methods for the characterization of oral wafers. Eur J Pharm Biopharm. 2009;73:195-201.
15. Boateng JS, Matthews KH, Auffret AD, Humphrey MJ, Stevens HNE, Eccleston GM. In vitro drug release studies of polymeric freeze-dried wafers and solvent-cast films using paracetamol as model soluble drug. Int J Pharm. 2009;378:66-72.
16. Boateng JS, Auffret AD, Matthews KH, Humphrey MJ, Stevens HNE, Eccleston GM. Characterisation of freeze-dried wafers and solvent evaporated films as potential drug delivery system to mucosal surfaces. Int J Pharm. 2010;389:24-31.
17. Abdelbary G, Eouani C, Prinderre P, Joachim J, Reynier J, Piccerelle P. Determination of the in vitro disintegration profile of rapidly disintegrating tablets and correlation with oral disintegration. Int J Pharm. 2005;292:29-41.
18. Darwish M, Kirby M, Robertson P, Tracewell W, Jiang JG. Absolute and relative bioavailability of fentanyl buccal tablet and oral transmucosal fentanyl citrate. J Clin Pharmacol. 2007;47:343-350.
19. Aronoff G, Brennan M, Pritchard D, Ginsberg B. Evidence-based oral transmucosal fentanyl citrate (OTFC) dosing guide lines. Pain Med. 2005;6:305-314.
20. Shojaei A. Buccal mucosa as a route for systemic drug delivery. J Pharm Sci. 1998;1:15-30.
21. Ghosh TK, Pfister WR. Drug Delivery to the Oral Cavity. Boca Raton, FL: CRC Press; 2005.
22. Mercadante S, Radbruck L, Davies A, et al. A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomized, crossover trial. Curr Med Res Opin. 2009;25:2805-2815.